Bosutinib Monohydrate is the monohydrate form of bosutinib, a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Unlike imatinib, bosutinib inhibits the autophosphorylation of both Abl and Src kinases, resulting in inhibition of cell growth and apoptosis. It is grouped under the following drug class(es): Antineoplastic agents, Kinase inhibitors and Tyrosine Kinase Inhibitors. Its therapeutic use is listed as antineoplastics. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Bosutinib hydrate, SKI-606 monohydrate, 3-Quinolinecarbonitrile, 4-((2, 4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)- and hydrate (1:1). Its PubChem CID is 11990828.
Bosutinib monohydrate
| CAS No | 918639-08-4 |
|---|---|
| Molecular Formula | C26H31Cl2N5O4 |
| Molecular Weight | 548.5 g/mol |
| Synonyms | 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile;hydrate |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Bosutinib Monohydrate is the monohydrate form of bosutinib, a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity.
The listed CAS number is 918639-08-4.
The listed molecular formula is C26H31Cl2N5O4.
The listed molecular weight is 548.5 g/mol.
4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile;hydrate.
The source lists Bosutinib hydrate, SKI-606 monohydrate, 3-Quinolinecarbonitrile, 4-((2, 4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)- and hydrate (1:1).